Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U06 Substudy 06E: Pembrolizumab + Investigational Agents +/- Chemotherapy in 1L Advanced Esophageal Cancer
NCT06780111Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2025
- Primary completion
- Jan 2032
- Countries
- 16
01
Overview
A Phase 2 trial of ifinatamab deruxtecan, sacituzumab tirumotecan in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Merck & Co.. Started Jul 2025; status: recruiting.
02
Drugs
ifinatamab deruxtecansacituzumab tirumotecan
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06780111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06780111.